“…Quantitative CT imaging has emerged as a valuable tool for exploring various lung disease manifestations, creating quantifiable biomarkers that can assess a wide range of risk factors and associated lung abnormalities ( Hoffman, 2022 ). Computational fluid and particle dynamics (CFPD) has also emerged as a powerful tool for assessing both the efficiency of drug delivery and the severity of respiratory diseases ( Lin et al, 2013 , Koullapis et al, 2021 , Zhou et al, 2024 , Yang et al, 2024 , Huang et al, 2021 , Kadota et al, 2022 ). Furthermore, in the era of big data, discovering patient clusters and unique biomarkers specific to these clusters is invaluable ( Lin et al, 2021 , Choi et al, 2017 ).…”